 | • レポートコード：MRC2-11QY01131 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は肝細胞癌治療薬のグローバル市場について調査・分析したレポートです。種類別（化学治療、小線源治療、アブレーション治療）市場規模、用途別（外科的切除、肝移植、アブレーション）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別肝細胞癌治療薬の競争状況、市場シェア ・世界の肝細胞癌治療薬市場：種類別市場規模 2015年-2020年（化学治療、小線源治療、アブレーション治療） ・世界の肝細胞癌治療薬市場：種類別市場規模予測 2021年-2026年（化学治療、小線源治療、アブレーション治療） ・世界の肝細胞癌治療薬市場：用途別市場規模 2015年-2020年（外科的切除、肝移植、アブレーション） ・世界の肝細胞癌治療薬市場：用途別市場規模予測 2021年-2026年（外科的切除、肝移植、アブレーション） ・北米の肝細胞癌治療薬市場分析：米国、カナダ ・ヨーロッパの肝細胞癌治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの肝細胞癌治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の肝細胞癌治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの肝細胞癌治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Johnson & Johnson、Gilead Sciences、Pacira、Sun Pharmaceutical、Luye Pharma、Sigma-Tau Group、Fudan-Zhangjiang、Teva Pharmaceutical、CSPC、Novartis、Kingond Pharm ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Hepatocellular Carcinoma Drug is a drug for treating Hepatocellular Carcinoma.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Hepatocellular Carcinoma Drug in US$ by following Product Segments.: Chemotherapy, Brachytherapy and Ablation Therapy.
Company profiles are primarily based on public domain information including company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Market Analysis and Insights: Global Hepatocellular Carcinoma Drug Market
The global Hepatocellular Carcinoma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hepatocellular Carcinoma Drug Scope and Market Size
Hepatocellular Carcinoma Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hepatocellular Carcinoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hepatocellular Carcinoma Drug market is segmented into
Chemotherapy
Brachytherapy
Ablation Therapy
Segment by Application, the Hepatocellular Carcinoma Drug market is segmented into
Surgical Resection
Liver Transplantation
Ablation
Regional and Country-level Analysis
The Hepatocellular Carcinoma Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hepatocellular Carcinoma Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hepatocellular Carcinoma Drug Market Share Analysis
Hepatocellular Carcinoma Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hepatocellular Carcinoma Drug business, the date to enter into the Hepatocellular Carcinoma Drug market, Hepatocellular Carcinoma Drug product introduction, recent developments, etc.
The major vendors covered:
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
1 Study Coverage
1.1 Hepatocellular Carcinoma Drug Product Introduction
1.2 Market Segments
1.3 Key Hepatocellular Carcinoma Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Type
1.4.2 Chemotherapy
1.4.3 Brachytherapy
1.4.4 Ablation Therapy
1.5 Market by Application
1.5.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Application
1.5.2 Surgical Resection
1.5.3 Liver Transplantation
1.5.4 Ablation
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hepatocellular Carcinoma Drug Market Size, Estimates and Forecasts
2.1.1 Global Hepatocellular Carcinoma Drug Revenue 2015-2026
2.1.2 Global Hepatocellular Carcinoma Drug Sales 2015-2026
2.2 Global Hepatocellular Carcinoma Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hepatocellular Carcinoma Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hepatocellular Carcinoma Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hepatocellular Carcinoma Drug Competitor Landscape by Players
3.1 Hepatocellular Carcinoma Drug Sales by Manufacturers
3.1.1 Hepatocellular Carcinoma Drug Sales by Manufacturers (2015-2020)
3.1.2 Hepatocellular Carcinoma Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Hepatocellular Carcinoma Drug Revenue by Manufacturers
3.2.1 Hepatocellular Carcinoma Drug Revenue by Manufacturers (2015-2020)
3.2.2 Hepatocellular Carcinoma Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hepatocellular Carcinoma Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Drug Revenue in 2019
3.2.5 Global Hepatocellular Carcinoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hepatocellular Carcinoma Drug Price by Manufacturers
3.4 Hepatocellular Carcinoma Drug Manufacturing Base Distribution, Product Types
3.4.1 Hepatocellular Carcinoma Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hepatocellular Carcinoma Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hepatocellular Carcinoma Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hepatocellular Carcinoma Drug Market Size by Type (2015-2020)
4.1.1 Global Hepatocellular Carcinoma Drug Sales by Type (2015-2020)
4.1.2 Global Hepatocellular Carcinoma Drug Revenue by Type (2015-2020)
4.1.3 Hepatocellular Carcinoma Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hepatocellular Carcinoma Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Hepatocellular Carcinoma Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Hepatocellular Carcinoma Drug Revenue Forecast by Type (2021-2026)
4.2.3 Hepatocellular Carcinoma Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hepatocellular Carcinoma Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hepatocellular Carcinoma Drug Market Size by Application (2015-2020)
5.1.1 Global Hepatocellular Carcinoma Drug Sales by Application (2015-2020)
5.1.2 Global Hepatocellular Carcinoma Drug Revenue by Application (2015-2020)
5.1.3 Hepatocellular Carcinoma Drug Price by Application (2015-2020)
5.2 Hepatocellular Carcinoma Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Hepatocellular Carcinoma Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Hepatocellular Carcinoma Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Hepatocellular Carcinoma Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hepatocellular Carcinoma Drug by Country
6.1.1 North America Hepatocellular Carcinoma Drug Sales by Country
6.1.2 North America Hepatocellular Carcinoma Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hepatocellular Carcinoma Drug Market Facts & Figures by Type
6.3 North America Hepatocellular Carcinoma Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Hepatocellular Carcinoma Drug by Country
7.1.1 Europe Hepatocellular Carcinoma Drug Sales by Country
7.1.2 Europe Hepatocellular Carcinoma Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hepatocellular Carcinoma Drug Market Facts & Figures by Type
7.3 Europe Hepatocellular Carcinoma Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hepatocellular Carcinoma Drug by Region
8.1.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Region
8.1.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hepatocellular Carcinoma Drug Market Facts & Figures by Type
8.3 Asia Pacific Hepatocellular Carcinoma Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hepatocellular Carcinoma Drug by Country
9.1.1 Latin America Hepatocellular Carcinoma Drug Sales by Country
9.1.2 Latin America Hepatocellular Carcinoma Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hepatocellular Carcinoma Drug Market Facts & Figures by Type
9.3 Central & South America Hepatocellular Carcinoma Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hepatocellular Carcinoma Drug by Country
10.1.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country
10.1.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hepatocellular Carcinoma Drug Market Facts & Figures by Type
10.3 Middle East and Africa Hepatocellular Carcinoma Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Description and Business Overview
11.1.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Johnson & Johnson Hepatocellular Carcinoma Drug Products Offered
11.1.5 Johnson & Johnson Related Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Corporation Information
11.2.2 Gilead Sciences Description and Business Overview
11.2.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Gilead Sciences Hepatocellular Carcinoma Drug Products Offered
11.2.5 Gilead Sciences Related Developments
11.3 Pacira
11.3.1 Pacira Corporation Information
11.3.2 Pacira Description and Business Overview
11.3.3 Pacira Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pacira Hepatocellular Carcinoma Drug Products Offered
11.3.5 Pacira Related Developments
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Corporation Information
11.4.2 Sun Pharmaceutical Description and Business Overview
11.4.3 Sun Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Products Offered
11.4.5 Sun Pharmaceutical Related Developments
11.5 Luye Pharma
11.5.1 Luye Pharma Corporation Information
11.5.2 Luye Pharma Description and Business Overview
11.5.3 Luye Pharma Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Luye Pharma Hepatocellular Carcinoma Drug Products Offered
11.5.5 Luye Pharma Related Developments
11.6 Sigma-Tau Group
11.6.1 Sigma-Tau Group Corporation Information
11.6.2 Sigma-Tau Group Description and Business Overview
11.6.3 Sigma-Tau Group Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Products Offered
11.6.5 Sigma-Tau Group Related Developments
11.7 Fudan-Zhangjiang
11.7.1 Fudan-Zhangjiang Corporation Information
11.7.2 Fudan-Zhangjiang Description and Business Overview
11.7.3 Fudan-Zhangjiang Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Products Offered
11.7.5 Fudan-Zhangjiang Related Developments
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Corporation Information
11.8.2 Teva Pharmaceutical Description and Business Overview
11.8.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Products Offered
11.8.5 Teva Pharmaceutical Related Developments
11.9 CSPC
11.9.1 CSPC Corporation Information
11.9.2 CSPC Description and Business Overview
11.9.3 CSPC Sales, Revenue and Gross Margin (2015-2020)
11.9.4 CSPC Hepatocellular Carcinoma Drug Products Offered
11.9.5 CSPC Related Developments
11.10 Novartis
11.10.1 Novartis Corporation Information
11.10.2 Novartis Description and Business Overview
11.10.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Novartis Hepatocellular Carcinoma Drug Products Offered
11.10.5 Novartis Related Developments
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Description and Business Overview
11.1.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Johnson & Johnson Hepatocellular Carcinoma Drug Products Offered
11.1.5 Johnson & Johnson Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hepatocellular Carcinoma Drug Market Estimates and Projections by Region
12.1.1 Global Hepatocellular Carcinoma Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Hepatocellular Carcinoma Drug Revenue Forecast by Regions 2021-2026
12.2 North America Hepatocellular Carcinoma Drug Market Size Forecast (2021-2026)
12.2.1 North America: Hepatocellular Carcinoma Drug Sales Forecast (2021-2026)
12.2.2 North America: Hepatocellular Carcinoma Drug Revenue Forecast (2021-2026)
12.2.3 North America: Hepatocellular Carcinoma Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Hepatocellular Carcinoma Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Hepatocellular Carcinoma Drug Sales Forecast (2021-2026)
12.3.2 Europe: Hepatocellular Carcinoma Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Hepatocellular Carcinoma Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hepatocellular Carcinoma Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hepatocellular Carcinoma Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hepatocellular Carcinoma Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hepatocellular Carcinoma Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Hepatocellular Carcinoma Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Hepatocellular Carcinoma Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Hepatocellular Carcinoma Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Hepatocellular Carcinoma Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hepatocellular Carcinoma Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hepatocellular Carcinoma Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hepatocellular Carcinoma Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hepatocellular Carcinoma Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hepatocellular Carcinoma Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hepatocellular Carcinoma Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hepatocellular Carcinoma Drug Market Segments
Table 2. Ranking of Global Top Hepatocellular Carcinoma Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Chemotherapy
Table 5. Major Manufacturers of Brachytherapy
Table 6. Major Manufacturers of Ablation Therapy
Table 7. Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Hepatocellular Carcinoma Drug Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Hepatocellular Carcinoma Drug Sales by Regions 2015-2020 (K Units)
Table 10. Global Hepatocellular Carcinoma Drug Sales Market Share by Regions (2015-2020)
Table 11. Global Hepatocellular Carcinoma Drug Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Hepatocellular Carcinoma Drug Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Hepatocellular Carcinoma Drug Sales Share by Manufacturers (2015-2020)
Table 14. Global Hepatocellular Carcinoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Hepatocellular Carcinoma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatocellular Carcinoma Drug as of 2019)
Table 16. Hepatocellular Carcinoma Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Hepatocellular Carcinoma Drug Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Hepatocellular Carcinoma Drug Price (2015-2020) (USD/Unit)
Table 19. Hepatocellular Carcinoma Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Hepatocellular Carcinoma Drug Product Type
Table 21. Date of International Manufacturers Enter into Hepatocellular Carcinoma Drug Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Hepatocellular Carcinoma Drug Sales by Type (2015-2020) (K Units)
Table 24. Global Hepatocellular Carcinoma Drug Sales Share by Type (2015-2020)
Table 25. Global Hepatocellular Carcinoma Drug Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Hepatocellular Carcinoma Drug Revenue Share by Type (2015-2020)
Table 27. Hepatocellular Carcinoma Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Hepatocellular Carcinoma Drug Sales by Application (2015-2020) (K Units)
Table 29. Global Hepatocellular Carcinoma Drug Sales Share by Application (2015-2020)
Table 30. North America Hepatocellular Carcinoma Drug Sales by Country (2015-2020) (K Units)
Table 31. North America Hepatocellular Carcinoma Drug Sales Market Share by Country (2015-2020)
Table 32. North America Hepatocellular Carcinoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Hepatocellular Carcinoma Drug Revenue Market Share by Country (2015-2020)
Table 34. North America Hepatocellular Carcinoma Drug Sales by Type (2015-2020) (K Units)
Table 35. North America Hepatocellular Carcinoma Drug Sales Market Share by Type (2015-2020)
Table 36. North America Hepatocellular Carcinoma Drug Sales by Application (2015-2020) (K Units)
Table 37. North America Hepatocellular Carcinoma Drug Sales Market Share by Application (2015-2020)
Table 38. Europe Hepatocellular Carcinoma Drug Sales by Country (2015-2020) (K Units)
Table 39. Europe Hepatocellular Carcinoma Drug Sales Market Share by Country (2015-2020)
Table 40. Europe Hepatocellular Carcinoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Hepatocellular Carcinoma Drug Revenue Market Share by Country (2015-2020)
Table 42. Europe Hepatocellular Carcinoma Drug Sales by Type (2015-2020) (K Units)
Table 43. Europe Hepatocellular Carcinoma Drug Sales Market Share by Type (2015-2020)
Table 44. Europe Hepatocellular Carcinoma Drug Sales by Application (2015-2020) (K Units)
Table 45. Europe Hepatocellular Carcinoma Drug Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Hepatocellular Carcinoma Drug Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Hepatocellular Carcinoma Drug Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Hepatocellular Carcinoma Drug Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Application (2015-2020)
Table 54. Latin America Hepatocellular Carcinoma Drug Sales by Country (2015-2020) (K Units)
Table 55. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Hepatocellular Carcinoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Hepatocellular Carcinoma Drug Revenue Market Share by Country (2015-2020)
Table 58. Latin America Hepatocellular Carcinoma Drug Sales by Type (2015-2020) (K Units)
Table 59. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Type (2015-2020)
Table 60. Latin America Hepatocellular Carcinoma Drug Sales by Application (2015-2020) (K Units)
Table 61. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Application (2015-2020)
Table 70. Johnson & Johnson Corporation Information
Table 71. Johnson & Johnson Description and Major Businesses
Table 72. Johnson & Johnson Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Johnson & Johnson Product
Table 74. Johnson & Johnson Recent Development
Table 75. Gilead Sciences Corporation Information
Table 76. Gilead Sciences Description and Major Businesses
Table 77. Gilead Sciences Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Gilead Sciences Product
Table 79. Gilead Sciences Recent Development
Table 80. Pacira Corporation Information
Table 81. Pacira Description and Major Businesses
Table 82. Pacira Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Pacira Product
Table 84. Pacira Recent Development
Table 85. Sun Pharmaceutical Corporation Information
Table 86. Sun Pharmaceutical Description and Major Businesses
Table 87. Sun Pharmaceutical Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Sun Pharmaceutical Product
Table 89. Sun Pharmaceutical Recent Development
Table 90. Luye Pharma Corporation Information
Table 91. Luye Pharma Description and Major Businesses
Table 92. Luye Pharma Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Luye Pharma Product
Table 94. Luye Pharma Recent Development
Table 95. Sigma-Tau Group Corporation Information
Table 96. Sigma-Tau Group Description and Major Businesses
Table 97. Sigma-Tau Group Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Sigma-Tau Group Product
Table 99. Sigma-Tau Group Recent Development
Table 100. Fudan-Zhangjiang Corporation Information
Table 101. Fudan-Zhangjiang Description and Major Businesses
Table 102. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Fudan-Zhangjiang Product
Table 104. Fudan-Zhangjiang Recent Development
Table 105. Teva Pharmaceutical Corporation Information
Table 106. Teva Pharmaceutical Description and Major Businesses
Table 107. Teva Pharmaceutical Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Teva Pharmaceutical Product
Table 109. Teva Pharmaceutical Recent Development
Table 110. CSPC Corporation Information
Table 111. CSPC Description and Major Businesses
Table 112. CSPC Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. CSPC Product
Table 114. CSPC Recent Development
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Major Businesses
Table 117. Novartis Hepatocellular Carcinoma Drug Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 118. Novartis Product
Table 119. Novartis Recent Development
Table 120. Kingond Pharm Corporation Information
Table 121. Kingond Pharm Description and Major Businesses
Table 122. Kingond Pharm Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 123. Kingond Pharm Product
Table 124. Kingond Pharm Recent Development
Table 125. Global Hepatocellular Carcinoma Drug Sales Forecast by Regions (2021-2026) (K Units)
Table 126. Global Hepatocellular Carcinoma Drug Sales Market Share Forecast by Regions (2021-2026)
Table 127. Global Hepatocellular Carcinoma Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 128. Global Hepatocellular Carcinoma Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 129. North America: Hepatocellular Carcinoma Drug Sales Forecast by Country (2021-2026) (K Units)
Table 130. North America: Hepatocellular Carcinoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 131. Europe: Hepatocellular Carcinoma Drug Sales Forecast by Country (2021-2026) (K Units)
Table 132. Europe: Hepatocellular Carcinoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Asia Pacific: Hepatocellular Carcinoma Drug Sales Forecast by Region (2021-2026) (K Units)
Table 134. Asia Pacific: Hepatocellular Carcinoma Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 135. Latin America: Hepatocellular Carcinoma Drug Sales Forecast by Country (2021-2026) (K Units)
Table 136. Latin America: Hepatocellular Carcinoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Middle East and Africa: Hepatocellular Carcinoma Drug Sales Forecast by Country (2021-2026) (K Units)
Table 138. Middle East and Africa: Hepatocellular Carcinoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 140. Key Challenges
Table 141. Market Risks
Table 142. Main Points Interviewed from Key Hepatocellular Carcinoma Drug Players
Table 143. Hepatocellular Carcinoma Drug Customers List
Table 144. Hepatocellular Carcinoma Drug Distributors List
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatocellular Carcinoma Drug Product Picture
Figure 2. Global Hepatocellular Carcinoma Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Chemotherapy Product Picture
Figure 4. Brachytherapy Product Picture
Figure 5. Ablation Therapy Product Picture
Figure 6. Global Hepatocellular Carcinoma Drug Sales Market Share by Application in 2020 & 2026
Figure 7. Surgical Resection
Figure 8. Liver Transplantation
Figure 9. Ablation
Figure 10. Hepatocellular Carcinoma Drug Report Years Considered
Figure 11. Global Hepatocellular Carcinoma Drug Market Size 2015-2026 (US$ Million)
Figure 12. Global Hepatocellular Carcinoma Drug Sales 2015-2026 (K Units)
Figure 13. Global Hepatocellular Carcinoma Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2015-2020)
Figure 15. Global Hepatocellular Carcinoma Drug Sales Market Share by Region in 2019
Figure 16. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2015-2020)
Figure 17. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region in 2019
Figure 18. Global Hepatocellular Carcinoma Drug Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Drug Revenue in 2019
Figure 20. Hepatocellular Carcinoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2015-2020)
Figure 22. Global Hepatocellular Carcinoma Drug Sales Market Share by Type in 2019
Figure 23. Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2015-2020)
Figure 24. Global Hepatocellular Carcinoma Drug Revenue Market Share by Type in 2019
Figure 25. Global Hepatocellular Carcinoma Drug Market Share by Price Range (2015-2020)
Figure 26. Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2015-2020)
Figure 27. Global Hepatocellular Carcinoma Drug Sales Market Share by Application in 2019
Figure 28. Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2015-2020)
Figure 29. Global Hepatocellular Carcinoma Drug Revenue Market Share by Application in 2019
Figure 30. North America Hepatocellular Carcinoma Drug Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Hepatocellular Carcinoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Hepatocellular Carcinoma Drug Sales Market Share by Country in 2019
Figure 33. North America Hepatocellular Carcinoma Drug Revenue Market Share by Country in 2019
Figure 34. U.S. Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Hepatocellular Carcinoma Drug Market Share by Type in 2019
Figure 39. North America Hepatocellular Carcinoma Drug Market Share by Application in 2019
Figure 40. Europe Hepatocellular Carcinoma Drug Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Hepatocellular Carcinoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Hepatocellular Carcinoma Drug Sales Market Share by Country in 2019
Figure 43. Europe Hepatocellular Carcinoma Drug Revenue Market Share by Country in 2019
Figure 44. Germany Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Hepatocellular Carcinoma Drug Market Share by Type in 2019
Figure 55. Europe Hepatocellular Carcinoma Drug Market Share by Application in 2019
Figure 56. Asia Pacific Hepatocellular Carcinoma Drug Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Hepatocellular Carcinoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Region in 2019
Figure 59. Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Region in 2019
Figure 60. China Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Hepatocellular Carcinoma Drug Market Share by Type in 2019
Figure 83. Asia Pacific Hepatocellular Carcinoma Drug Market Share by Application in 2019
Figure 84. Latin America Hepatocellular Carcinoma Drug Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Hepatocellular Carcinoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Country in 2019
Figure 87. Latin America Hepatocellular Carcinoma Drug Revenue Market Share by Country in 2019
Figure 88. Mexico Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Hepatocellular Carcinoma Drug Market Share by Type in 2019
Figure 95. Latin America Hepatocellular Carcinoma Drug Market Share by Application in 2019
Figure 96. Middle East and Africa Hepatocellular Carcinoma Drug Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Country in 2019
Figure 100. Turkey Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Hepatocellular Carcinoma Drug Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Hepatocellular Carcinoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Hepatocellular Carcinoma Drug Market Share by Type in 2019
Figure 107. Middle East and Africa Hepatocellular Carcinoma Drug Market Share by Application in 2019
Figure 108. North America Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Hepatocellular Carcinoma Drug Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
神経内分泌がんの世界市場（～2026年） Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the …- 基底細胞がん（BCC）治療薬の世界市場（～2026年） Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening…
- 副腎皮質がん治療の世界市場（～2026年） Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. T…
- 尿路上皮がん治療の世界市場（～2026年） Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar …
- 結腸・直腸がんの世界市場（～2026年） Market Analysis and Insights: Global Colon & Rectal Carcinoma Market The global Colon & Rectal Carcinoma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Colon & Rectal Carcinoma Scope and Market Size Colon & Rectal Car…